<DOC>
	<DOCNO>NCT00364000</DOCNO>
	<brief_summary>End-stage renal disease ( ESRD ) state increase arterial stiffness extensive vessel calcification , compare non-renal population . Both arterial stiffness arterial calcification potent predictor all-cause cardiovascular mortality ESRD patient . Several study document direct relationship extent severity arterial/coronary calcification outcome dialysis patient . The relationship strong matter arterial calcification quantify electron-beam compute tomography radiological calcification score . Calcifications early progressive event patient . PWV strongly relate degree sonographic determine arterial calcification EBCT-derived coronary artery calcium score chronic kidney disease patient . Calcium-based phosphate binder associate progressive coronary artery aortic calcification , especially mineral metabolism well control . According recent study , sevelamer hydrochloride potent non-calcium-containing phosphate binder , well tolerate ESRD . Compared calcium-based phosphate binder , sevelamer less likely cause hypercalcemia , low level PTH , progressive coronary aortic calcification hemodialysis patient . Moreover , sevelamer favorable effect lipid profile . Less known relationship sevelamer treatment progression arterial stiffness . To date , one single study examine influence sevelamer ( versus calcium carbonate ) evolution arterial stiffness small number ( N=15 ) haemodialysis patient . These study use patient historical control , thus methodologically rather weak . Moreover , follow-up quite short - 6 month . The aim trial quantify , randomize opened-labeled controlled trial effect sevelamer hydrochloride evolution arterial stiffness parameter ( pulse wave velocity augmentation index ) chronic haemodialysis patient correlate parameter arterial calcification assess previous described radiological score arterial calcification echocardiographic parameter ( leave ventricular hypertrophy , LV dilatation , systolic diastolic dysfunction ) .</brief_summary>
	<brief_title>Arterial Stiffness Calcifications Haemodialysis Patients Sevelamer Calcium Acetate</brief_title>
	<detailed_description>End-stage renal disease ( ESRD ) state increase arterial stiffness extensive vessel calcification , compare non-renal population . Both arterial stiffness arterial calcification potent predictor all-cause cardiovascular mortality ESRD patient . Underlying mechanism increase stiffness uremia well-defined , may include : chronic fluid overload , arterial calcification , microinflammation , increase sympathetic hyperactivity , activation renin-angiotensin system , increase lipid oxidation , abnormality nitric oxide system . Several study document direct relationship extent severity arterial/coronary calcification outcome dialysis patient . The relationship strong matter arterial calcification quantify electron-beam compute tomography radiological calcification score . Calcifications early progressive event patient . PWV strongly relate degree sonographic determine arterial calcification EBCT-derived coronary artery calcium score chronic kidney disease patient . Calcium-based phosphate binder associate progressive coronary artery aortic calcification , especially mineral metabolism well control . Sevelamer hydrochloride potent non-calcium-containing phosphate binder , well tolerate ESRD . Compared calcium-based phosphate binder , sevelamer less likely cause hypercalcemia , low level PTH , progressive coronary aortic calcification hemodialysis patient . Moreover , sevelamer favorable effect lipid profile . Less known relationship sevelamer treatment progression arterial stiffness . To date , one single study examine influence sevelamer ( versus calcium carbonate ) evolution arterial stiffness 15 HD patient . These study use patient historical control , thus methodologically rather weak . Moreover , follow-up quite short - 6 month . The aim study quantify , randomize opened-labeled controlled trial effect sevelamer hydrochloride evolution arterial stiffness parameter ( pulse wave velocity augmentation index ) chronic haemodialysis patient correlate parameter arterial calcification assess previous described radiological score arterial calcification echocardiographic parameter ( leave ventricular hypertrophy , LV dilatation , systolic diastolic dysfunction ) 240 chronic clinical stable ( young-to-medium-aged ) haemodialysis patient include . Follow-up : 12 month After screen , patient enter washout period currently use phosphate binder 2 week . All patient hyperphosphatemia ( &gt; 1.8 mmol/l ) wash-out period eligible randomization treatment phase . Stratification consider Framingham calcification score , age , gender , diabetes , HD vintage The patient randomize ( computer-generated ) 1:1 ratio open label sevelamer ( RenagelR ) 800 mg tablet calcium acetate 670 mg tablet . Because size , appearance taste tablet , neither subject investigator blind . Adherence treatment assess regular bill count . The start dose sevelamer calcium acetate determine replace phosphate binder use patient prior washout period gram gram basis . The dose phosphate binder titrate achieve serum phosphorus level target range 1-1.6 mmol/L serum calcium level &lt; 2.6 mmol/L . The maximum elemental calcium dose/day calcium acetate arm exceed 1.5 g. Serum ionize calcium adjust serum albumin concentration use formula : adjust Ca = total measure calcium +0.8 x ( 4.0-albumin g/dL ) . After 4 week , dose phosphate binder , vitamin D analogue dialysate calcium concentration titrate reach target range . Study conduction conduct strictly compliance Declaration Helsinki Committees Human Research participate centers/Universities The K/DOQI target serum phosphate , serum-calcium PTH aim study . Data intact parathormone , serum-calcium phosphate , Ca-P product collect monthly first three month , every 3 month later . Vitamin D allowance study PTH raise &gt; 500 pg/ml ; vitamin D serum calcium &gt; 2.6 mmol/L Analysis include : - correlation PWV , AIx , calcification score Ca-P metabolism parameter , lipid parameter etc - capability reach N/KDOQI guideline regard control secondary hyperparathyroidism - sevelamer hydrochloride versus calcium acetate - stratification PWV AIx dynamic accord different category The publish reference literature Takenaka et al ( NDT 2005 ) ; show small study 6 month sevelamer treatment PWV decrease 14.56 m/s 13.34 m/s i.e . decrease approximatively 9 % pre-Sevelamer value . If normalize BP ( PWV divide correspond BP level ) PWV/BP decrease 10.2 m/s/mmHg 9.3 m/s/mmHg - i.e . decrease approximatively 9 % pre-Sevelamer value . Of note , previous 6 month , CaCO3 , PWV increase significantly 30 40 % baseline study value ( study Takenaka cross-over design : 6-months CaCO3 follow 6-months Sevelamer ) . Also information provide AIx . There information literature impact Sevelamer EID ( GTN ) - vascular function EDD ( flow-dependent hyperemia beta2 agonist stimulation ) -vascular function . In experience , mean PWV 7.19+/-1.88 m/s , correct correspond BP value : PWV/BP = 5.14 +/- 1.3 m/s/mmHg . AIx typically 27.9Â±11.9 % HD patient . If assume Sevelamer group ( `` treatment group '' ) 9 % decrease PWV 6 month , baseline , Ca-binder group ( `` control group '' ) change ( i.e . increase PWV - `` conservative approach '' , different Takenaka 's result increase PWV report - see ) , standard deviation PWV 1.88 m/s experience 1.3 m/s/mmHg , ratio 1 control thre treatment arm , power 80 % confidence interval 95 % need 108 patient arm ( 105 PWV/BP use ) , 216 total . This also sufficient power detect decrease AIx 4.6 % 16.5 % baseline treatment arm . This usually less recorded different acute intervention ( GTN , salbutamol , dialysis session ) transplantation HD patient . Compliance good unit transplantation rare . Therefore expect dropout rate 10 % . Thus final study population 240 patient . 120 patient receive Sevelamer 6 month .</detailed_description>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium acetate</mesh_term>
	<criteria>3 month haemodialysis willingness participate age 1860 yr predialysis blood pressure 120160 mmHg last month prior initiation study recent ( &lt; 1 Mo ) addition new antihypertensive drug iPTH entry 200800 pg/mL ( per severe hyperparathyroidism ) serum calcium entry 2.22.6 mmol/L haemodynamic instability uncontrolled hypertension severe , debilitate disease associate reduce survival major cardiovascular event last 12 month study cinacalcet therapy study entrance history parathyroidectomy document history poor compliance serious gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>haemodialysis</keyword>
	<keyword>hyperphosphatemia</keyword>
	<keyword>sevelamer</keyword>
	<keyword>calcium acetate</keyword>
</DOC>